Breaking Finance News

Zacks Investment Research downgraded Tokai Pharmaceuticals Inc (NASDAQ:TKAI) to Hold in a report released today.

Just yesterday Tokai Pharmaceuticals Inc (NASDAQ:TKAI) traded 0.00% even at $1.61. Tokai Pharmaceuticals Inc’s 50-day moving average is $1.29 and its 200-day moving average is $4.47. The last closing price is down -65.32% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 554,197 shares of TKAI traded hands, down from an average trading volume of 1,336,110

Zacks Investment Research has downgraded Tokai Pharmaceuticals Inc (NASDAQ:TKAI) to Hold in a report released on Thursday October 06, 2016.

Previously on 9/28/2016, Zacks Investment Research reported on Tokai Pharmaceuticals Inc (NASDAQ:TKAI) increased the target price from $0.00 to $1.75. At the time, this indicated a possible upside of 0.23%.

Recent Performance Chart

Tokai Pharmaceuticals Inc (NASDAQ:TKAI)

Tokai Pharmaceuticals Inc has 52 week low of $0.98 and a 52 week high of $12.93 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 6 brokers have issued a research note on the company. The average stock price target is $21.17 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Tokai Pharmaceuticals Inc (NASDAQ:TKAI)

Tokai Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Company's lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of second-generation androgen signaling inhibitors, while also introducing a third mechanism-androgen receptor degradation. The Company develops galeterone for the treatment of patients with metastatic castration-resistant prostate cancer, or mCRPC. The Company is conducting a pivotal Phase III clinical trial comparing galeterone to Xtandi (enzalutamide) in approximately 148 treatment-naive mCRPC patients whose prostate tumors express the AR-V7 splice variant. The Company refers clinical trial as ARMOR3-SV, a precision-medicine based pivotal clinical trial in prostate cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.